LENZ Therapeutics Inc
LENZ
View Detailed Chart
41.690USD
-0.540-1.28%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
1.19BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.28%
5 Days
-0.05%
1 Month
+10.15%
6 Months
+76.73%
Year to Date
+44.41%
1 Year
+97.58%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Strong Buy
Current Rating
49.714
Target Price
+20.40%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Undervalued
The company’s latest PE is -25.96, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 29.52M shares, decreasing 2.12% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.29M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.11.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Ticker SymbolLENZ
CompanyLENZ Therapeutics Inc
CEOMr. Evert (Eef) Schimmelpennink
Website
Related Instruments
-0.46%
-0.61%
-1.75%
+3.12%
+3.03%
-0.93%
+2.06%
+3.67%
+2.50%
+3.53%
+0.35%
+0.62%
+1.25%
+3.06%
-0.57%
+1.35%
+2.74%
+4.60%
+2.77%
+4.51%
